Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Product Name : MTX110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study
Details : The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Product Name : MTX110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co.
Deal Size : $3.0 million
Deal Type : Public Offering
Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million
Details : The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Product Name : MTX110
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co.
Deal Size : $3.0 million
Deal Type : Public Offering